Drug trial aims to ease heart strain in rare blood vessel disorder
NCT ID NCT07445347
Summary
This study is testing whether a drug called bevacizumab can help people with hereditary hemorrhagic telangiectasia (HHT) who have severe liver problems that are putting extra strain on their heart. It will involve 111 patients in France who are already receiving this drug through a special access program. Researchers will check if the treatment improves heart and liver measurements and is well-tolerated over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier universitaire de Poitiers
Poitiers, 86000, France
Conditions
Explore the condition pages connected to this study.